Arming antibodies: prospects and challenges for immunoconjugates (Q34449555)

2 August 2017

1 reference

title

Arming antibodies: prospects and challenges for immunoconjugates (English)

1 reference

2 August 2017

1 reference

Anna M Wu

1

1 reference

2 August 2017

Peter D Senter

series ordinal

2

1 reference

2 August 2017

publication date

1 September 2005

1 reference

2 August 2017

1 reference

2 August 2017

volume

23

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

1137-1146

1 reference

Natural and designer binding sites made by phage display technology

2 August 2017

cites work

1 reference

7 January 2021

Yeast display of antibody fragments: a discovery and characterization platform.

1 reference

7 January 2021

In-vitro protein evolution by ribosome display and mRNA display

1 reference

7 January 2021

Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics

1 reference

7 January 2021

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

1 reference

7 January 2021

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

7 January 2021

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier

1 reference

7 January 2021

Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy.

1 reference

7 January 2021

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

1 reference

7 January 2021

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

7 January 2021

Antibody-targeted radiation cancer therapy

1 reference

7 January 2021

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments

1 reference

7 January 2021

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

1 reference

7 January 2021

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand

1 reference

7 January 2021

Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals

1 reference

7 January 2021

Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody

1 reference

7 January 2021

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications

1 reference

7 January 2021

Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex

1 reference

7 January 2021

Converting weak binders into infinite binders

1 reference

7 January 2021

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody

1 reference

7 January 2021

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting

1 reference

7 January 2021

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging

1 reference

7 January 2021

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

1 reference

7 January 2021

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

1 reference

7 January 2021

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

1 reference

7 January 2021

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

1 reference

7 January 2021

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice

1 reference

7 January 2021

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

7 January 2021

Progress in immunoconjugate cancer therapeutics

1 reference

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

7 January 2021

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)

1 reference

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

7 January 2021

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

1 reference

7 January 2021

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

1 reference

7 January 2021

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

1 reference

7 January 2021

An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker

1 reference

7 January 2021

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

7 January 2021

Mylotarg: antibody-targeted chemotherapy comes of age.

1 reference

7 January 2021

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

7 January 2021

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

1 reference

7 January 2021

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

1 reference

7 January 2021

Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts

1 reference

7 January 2021

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

7 January 2021

An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance

1 reference

7 January 2021

Immunotoxins: magic bullets or misguided missiles?

1 reference

7 January 2021

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

7 January 2021

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

1 reference

7 January 2021

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

1 reference

7 January 2021

Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin

1 reference

7 January 2021

Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin

1 reference

7 January 2021

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

1 reference

7 January 2021

Synthesis of an immunoconjugate of camptothecin

1 reference

7 January 2021

Monoclonal antibody mediated intracellular targeting of tallysomycin S(10b)

1 reference

7 January 2021

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

7 January 2021

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

7 January 2021

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer

1 reference

7 January 2021

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

1 reference

7 January 2021

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

1 reference

7 January 2021

Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.

1 reference

7 January 2021

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo

1 reference

7 January 2021

Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats

1 reference

7 January 2021

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

1 reference

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

7 January 2021

Pretargeting with amplification using polymeric peptide nucleic acid

1 reference

7 January 2021

Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)

1 reference

7 January 2021

Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy

1 reference

7 January 2021

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

1 reference

7 January 2021

Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells

1 reference

7 January 2021

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

1 reference

7 January 2021

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

1 reference

7 January 2021

Efficient cancer therapy with a nanobody-based conjugate

1 reference

7 January 2021

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

1 reference

7 January 2021

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

1 reference

7 January 2021

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

1 reference

7 January 2021

Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT1141

1 reference

2 August 2017

1 reference